Aytu BioPharma (NASDAQ:AYTU) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Aytu BioPharma (NASDAQ:AYTU) from a hold rating to a strong sell rating in a report issued on Monday morning,Zacks reports.

Other equities research analysts also recently issued research reports about the company. Ascendiant Capital Markets raised their price target on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $14.50.

Aytu BioPharma Stock Performance

Aytu BioPharma stock opened at $2.05 on Monday. Aytu BioPharma has a fifty-two week low of $1.80 and a fifty-two week high of $3.07. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.00 and a current ratio of 1.13. The stock has a market cap of $22.28 million, a P/E ratio of -1.23 and a beta of 0.17. The firm’s fifty day moving average price is $2.22 and its 200-day moving average price is $2.30.

Hedge Funds Weigh In On Aytu BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in Aytu BioPharma by 23.3% in the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after buying an additional 8,222 shares during the period. BlackRock Inc. purchased a new position in shares of Aytu BioPharma during the 2nd quarter worth approximately $49,000. Persistent Asset Partners Ltd purchased a new position in shares of Aytu BioPharma during the 2nd quarter worth approximately $82,000. Arete Wealth Advisors LLC bought a new position in shares of Aytu BioPharma in the 1st quarter worth approximately $135,000. Finally, Crown Advisors Management Inc. bought a new position in shares of Aytu BioPharma in the 2nd quarter worth approximately $430,000. 33.49% of the stock is owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs.

Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR.